PLX-4000 is an investigational drug developed by Plexxikon, designed to target specific genetic mutations in cancer cells. It works by inhibiting certain proteins that promote tumor growth, potentially slowing down or stopping the progression of various cancers. Currently, PLX-4000 is undergoing clinical trials to evaluate its safety and effectiveness in patients with specific types of tumors. Researchers aim to determine how well it can improve treatment outcomes compared to existing therapies, making it a promising candidate in the field of targeted cancer treatment.